Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

New drug approval success rate in Europe in 2009


This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Czerepak, E. A. & Ryser, S. Drug approvals and failures: implications for alliances. Nature Rev. Drug Discov. 7, 197–198 (2008).

    Article  CAS  Google Scholar 

  2. European Commission. Notice to Applicants. Volume 2A: procedures for marketing authorisation. Chapter 1: marketing authorisation. November 2005. EC website [online], (2005).

  3. European Medicines Agency. Human medicines. EMA website [online], (2010).

  4. Pignatti, F. et al. The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome. Eur. J. Clin. Pharmacol. 58, 573–580 (2002).

    Article  PubMed  Google Scholar 

  5. European Medicines Agency. Withdrawal assessment report for vorinostat MSD 100 mg hard capsules. EMA website [online], (2008).

  6. Regnstrom, J. et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39–48 (2010).

    Article  PubMed  Google Scholar 

  7. Hughes, B. 2009 FDA drug approvals. Nature Rev. Drug Discov. 9, 89–92 (2010).

    Article  CAS  Google Scholar 

  8. Eichler, H.-G. et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nature Rev. Drug Discov. 7, 818–826 (2008).

    Article  CAS  Google Scholar 

  9. European Medicines Agency. Reflection paper on benefit–risk assessment methods in the context of the evaluation of marketing authorisation applications of medicinal products for human use. EMA website [online], (2008).

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (table)

MAAs for new active substances in the EU with a negative outcome in 2009 (PDF 144 kb)

Supplementary information S2 (box)

Definition of a new active substance in the European Union (PDF 139 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eichler, HG., Aronsson, B., Abadie, E. et al. New drug approval success rate in Europe in 2009. Nat Rev Drug Discov 9, 355–356 (2010).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research